Biofrontera Inc. Warrants (BFRIW NASDAQ) stock market data APIs
$0.0395
-0.01(-25.3%)
as of May 6, 2026
Try our APIs with
free plan!
Biofrontera Inc. Warrants Financial Data Overview
Price chart is built with
Anychart
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Prev. Close
0.0395
Open
0.0291
High
0.0395
Low
0.0291
52 wk Range
0.029-0.277
Market Cap
0
Revenue
41 705 K
EPS
-0.4576
Beta
0.911
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Biofrontera Inc. Warrants data using free add-ons & libraries
Get Biofrontera Inc. Warrants Fundamental Data
Biofrontera Inc. Warrants Fundamental data includes:
- Net Revenue: 41 705 K
- EBITDA: -11 210 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Biofrontera Inc. Warrants Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Biofrontera Inc. Warrants News
New
Biofrontera Inc. Q4 2025 Earnings Call Summary
Biofrontera Inc. Q4 2025 Earnings Call Summary - Moby Strategic Pivot and Commercial Execution Achieved record annual revenue of $41.7 million, driven by a 10% increase in Ameluz unit volumes and re...
Biofrontera signals enhanced operating leverage as U.S. independence and new patent reshape outlook
Earnings Call Insights: Biofrontera Inc. (BFRI) Q2 2025 MANAGEMENT VIEW * CEO Hermann Luebbert highlighted a "record breaking" performance in the first half of 2025, driven by a shift in customer ...
Biofrontera Inc. Announces Voting Results from 2022 Annual Meeting of Stockholders
WOBURN, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the fi...
Biofrontera Inc. to Participate in Benchmark’s 11th Annual Discovery One-on-One Investor Conference
WOBURN, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that t...
Get Biofrontera Inc. Warrants fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
